| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD163 |
| Uniprot No | Q86VB7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 78-168aa |
| 氨基酸序列 | NGWSMEAVSVICNQLGCPTAIKAPGWANSSAGSGRIWMDHVSCRGNESAL WDCKHDGWGKHSNCTHQQDAGVTCSDGSNLEMRLTRGGNMC |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD163重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*"Structural basis for receptor recognition of the human CD163 soluble domain—A recombinant protein study"*
**作者**：Etzerodt A, Moestrup SK
**摘要**：该研究通过重组表达技术制备了人源CD163的可溶性结构域(sCD163)，解析了其晶体结构，并揭示了其与血红蛋白-触珠蛋白复合体的结合机制，为炎症相关疾病的治疗提供了结构基础。
2. **文献名称**：*"Production and functional characterization of recombinant CD163 fused to Fc region: A therapeutic potential for hemoglobin clearance"*
**作者**：Fabriek BO, van Bruggen R
**摘要**：作者构建了CD163-Fc重组融合蛋白，证实其能有效结合游离血红蛋白，并在细胞实验中展示出增强的清除能力，提示其在溶血性疾病中的治疗潜力。
3. **文献名称**：*"Elevated levels of soluble CD163 in sera of patients with sepsis: Association with outcome and inflammatory response"*
**作者**：Møller HJ, Moestrup SK
**摘要**：该研究利用重组sCD163蛋白作为标准物，检测脓毒症患者血清中sCD163水平，发现其与疾病严重程度及炎症因子水平呈正相关，提示其作为生物标志物的可能性。
4. **文献名称**：*"Recombinant porcine CD163 reduces PRRSV infection by blocking viral receptor binding in vitro"*
**作者**：Van Gorp H, Van Breedam W
**摘要**：研究通过重组表达猪CD163蛋白，证实其能体外抑制猪繁殖与呼吸综合征病毒(PRRSV)对宿主细胞的感染，机制为竞争性阻断病毒与膜结合CD163受体的相互作用。
这些文献涵盖了CD163重组蛋白的结构解析、治疗应用、生物标志物开发及抗病毒机制，反映了其多方面的研究价值。
CD163. a member of the scavenger receptor cysteine-rich (SRCR) superfamily, is a transmembrane glycoprotein predominantly expressed on monocytes and macrophages, particularly the anti-inflammatory M2 macrophage subset. Its structure includes nine SRCR domains, with the fifth domain critical for binding hemoglobin-haptoglobin (Hb-Hp) complexes. CD163 plays a dual role as a hemoglobin scavenger receptor and a regulator of innate immune responses. By clearing free hemoglobin released during hemolysis, it mitigates oxidative tissue damage and iron toxicity. Additionally, it modulates inflammatory signaling through interactions with toll-like receptors (TLRs) and secretion of anti-inflammatory cytokines like IL-10.
Recombinant CD163 proteins, typically produced in mammalian or insect expression systems, retain the functional extracellular domains to mimic native receptor-ligand interactions. These proteins often include tags (e.g., His-tag) for purification and detection. Researchers use recombinant CD163 to study macrophage polarization, inflammatory pathways, and host-pathogen interactions, as some pathogens exploit CD163 for cellular entry. In clinical contexts, soluble CD163 (sCD163) levels in serum serve as a biomarker for macrophage activation in conditions like sepsis, atherosclerosis, and viral infections (e.g., COVID-19), correlating with disease severity.
Therapeutic applications of recombinant CD163 focus on targeting inflammatory diseases or enhancing hemoglobin clearance in hemolytic disorders. Its role in resolving inflammation and promoting tissue repair also makes it a candidate for immunomodulatory therapies. However, challenges remain in understanding tissue-specific CD163 isoforms and signaling nuances. Overall, recombinant CD163 is a vital tool for dissecting macrophage biology and developing diagnostic or therapeutic strategies for inflammation-related pathologies.
×
